Corbion announces strong first quarter 2025 results, well on track to deliver full-year outlook

Core Insights - Corbion reported strong Q1 2025 results, with significant growth in sales and adjusted EBITDA, affirming its full-year outlook [1][5] Financial Performance - Organic sales growth of 7.9% driven by volume/mix growth of 8.4%, while prices decreased by 0.5% [2] - Total sales reached €329.7 million, up 9.8% from €300.4 million in Q1 2024 [2] - Adjusted EBITDA increased to €54.4 million, reflecting a 57.7% rise, with an organic increase of 53.9% [2][5] - Operating profit surged to €34.0 million, marking a 193.1% increase, with an organic growth of 186.2% [2][5] - Adjusted EBITDA margin improved to 16.5%, up from 11.5% in the previous year [2] Business Segments Performance - In Functional Ingredients & Solutions, all three businesses (Food, Biochemicals, and Lactic acid to the PLA JV) achieved volume/mix growth, with margins exceeding 12% [3] - Health & Nutrition segment also saw volume/mix growth across all three businesses (Nutrition, Biomedical polymers, and Pharma), with adjusted EBITDA margins exceeding 30% [3] Strategic Outlook - The company remains committed to executing its strategy amidst macro-economic and geopolitical uncertainties, on track to meet 2025 guidance for volume/mix, adjusted EBITDA, and free cash flow [4]